Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Searle CoKAR:SEARL -2.15%69 Debt-to-EBITDA is 1.20 as of Mar. 2026, which is 17% below its 10-year median of 1.45. GuruFocus rates KAR:SEARL with a GF Score™ of 69/100 and a GF Value™ of ₨75.22 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 675 Drug Manufacturers companies, The Searle Co ranks better than 60.15% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for The Searle Co's Debt-to-EBITDA or its related term are showing as below:
KAR:SEARL'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.4 Med: 1.45 Max: 4.73
Current: 1.05
During the past 13 years, the highest Debt-to-EBITDA Ratio of The Searle Co was 4.73. The lowest was 0.40. And the median was 1.45.
KAR:SEARL's Debt-to-EBITDA is ranked better than 60.15% of 675
companies
in the Drug Manufacturers industry
Industry Median: 1.64
vs KAR:SEARL: 1.05
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The Searle Co Debt-to-EBITDA Related Terms
The Searle Co Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for The Searle Co's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, The Searle Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Searle Co Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, The Searle Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where The Searle Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
The Searle Co (KAR:SEARL) has a Debt-to-EBITDA of 1.20 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on The Searle Co. This is 17% below median its historical median of 1.45. Over the past decade, The Searle Co's Debt-to-EBITDA has ranged from 0.40 to 4.73. According to the industry distribution chart, The Searle Co ranks #269 out of 675 companies in the Drug Manufacturers industry, placing it in the top 39.9%.
Is The Searle Co's Debt-to-EBITDA too high?
The Searle Co's current Debt-to-EBITDA of 1.20 is 17% below median its 10-year median of 1.45. Over the past 10 years, this metric has ranged from a low of 0.40 to a high of 4.73. The Drug Manufacturers industry median Debt-to-EBITDA is 1.64. The Searle Co's value of 1.20 is 26.8% below this industry median. Based on the distribution chart, The Searle Co ranks #269 out of 675 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, The Searle Co has a GF Score™ of 69/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does The Searle Co's Debt-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, The Searle Co ranks #269 out of 675 companies for Debt-to-EBITDA. This puts The Searle Co in the upper half of its industry. The industry median Debt-to-EBITDA is 1.64. The Searle Co's value of 1.20 is 26.8% below this benchmark. Historically, The Searle Co's own Debt-to-EBITDA has ranged from 0.40 to 4.73 over the past decade. While the company's 10-year median is 1.45 vs. the industry median of 1.64, The Searle Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.64, based on 675 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. The Searle Co's current Debt-to-EBITDA of 1.20 is 26.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on The Searle Co. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The Searle Co's current Debt-to-EBITDA is 1.20, which is 17% below median its own 10-year median of 1.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Searle Co stock overvalued right now?
Based on GuruFocus' analysis, The Searle Co (KAR:SEARL) is currently considered Modestly Overvalued. The stock's GF Value™ is ₨75.22, compared to a current price of ₨84.83 — trading 12.8% above its estimated fair value. The current Debt-to-EBITDA is 1.20, which is 17% below median its 10-year median of 1.45 and 26.8% below the Drug Manufacturers industry median of 1.64. The Searle Co's overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For The Searle Co (KAR:SEARL), the current Debt-to-EBITDA is 1.20 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is The Searle Co (KAR:SEARL) Overvalued in 2026?
Based on GuruFocus' analysis, The Searle Co stock appears to be overvalued.
The current stock price of ₨84.83 is trading 12.8% above its estimated GF Value™ of ₨75.22.
GuruFocus considers The Searle Co to be Modestly Overvalued.
Key valuation signals for KAR:SEARL:
Debt-to-EBITDA: 1.20 (17% below median its 10-year median of 1.45)
GF Value™: ₨75.22 vs. price of ₨84.83 (12.8% above fair value)
Industry Position: 26.8% below the Drug Manufacturers median (#269 of 675)
No single metric tells the full story. See the KAR:SEARL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
The Searle Co Ltd is principally engaged in the manufacturing and sale of pharmaceutical, consumer health, and nutritional products. It manufactures and sells products such as Semavi, Dalimab, Extor, Tramal, Rotec, Hylixi, Emsyn, and many more, focusing on various therapeutic areas like cardiovascular, antibiotics, nutrition, respiratory care, gastroenterology, oncology, hepatology, neurology and psychiatry, probiotics, antibiotics, and nutritional care. Additionally, the group offers medical devices and disposables, health supplements, and various nutritional consumable products. The majority of the group's revenue consists of pharmaceutical sales. Geographically, it generates maximum revenue from Pakistan, and rest from Sri Lanka, Cambodia, Myanmar, Oman, Vietnam, and other countries.
69GF Score
Get the complete analysis for KAR:SEARL
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KAR:SEARL has been successfully added to your 
